Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50).
Reduced Hb-O(2) affinity facilitates O(2) release to tissue but may impair pulmonary O(2) uptake, affecting cardiac output and systemic vascular resistance (SVR). We studied the effects of shifting the O(2)-dissociation curve (ODC) to the right with a continuous infusion of RSR13, an allosteric modifier of Hb, and of different inspired O(2) fractions (FI(O(2))) on arterial O(2) saturations (Sa(O(2))) in Hb and on hemodynamics in nonanesthetized rats. At an FI(O(2)) of 0.21, Sa(O(2)) fell during RSR13 from 95 to 81%. Elevation of FI(O(2)) to 0.30 returned Sa(O(2)) to baseline in the RSR13 group. The decrease in mean arterial pressure (MAP) was significantly greater in the control than in the RSR13 group at 30% O(2). Cardiac index (CI) increased only during RSR13 at 21% O(2) and returned to baseline at 30% O(2). In contrast, SVR decreased after RSR13 was infused at 21% O(2) but returned to baseline at 30%O(2), whereas controls showed the opposite, a sustained SVR. In the follow-up period, when 21 O(2)% was reestablished and mild anemia was present, MAP and SVR fell significantly more in controls, whereas CI only increased in controls. Lactate was significantly lower in the RSR13 than in the control group during RSR13 and the follow-up period. These results demonstrate that 1) continuous infusion of RSR13 produces a constant shift in the O(2) tension at which Hb is 50% saturated (P(50)), 2) FI(O(2)) of 0.30 compensates for the effects of increased P(50) on pulmonary O(2) loading, and 3) right-shifted ODC combined with supplemental O(2) may improve tissue O(2) availability.
Eichelbrönner
O
O
A. C. Burton Vascular Biology Laboratory, University of Western Ontario, London, Ontario, Canada N6A 4G5.
Sielenkämper
A
A
D'Almeida
M
M
Ellis
C G
CG
Sibbald
W J
WJ
Chin-Yee
I H
IH
D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology*; D006454:Hemoglobins / Q000187:drug effects* / Q000378:metabolism*; D019344:Lactic Acid / Q000378:metabolism; D008297:Male; D010100:Oxygen / Q000378:metabolism*; D010101:Oxygen Consumption; D011422:Propionates / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000814:Aniline Compounds; D006454:Hemoglobins; D011422:Propionates; D019344:Lactic Acid; C067396:efaproxiral; D010100:Oxygen